7,807 IDEXX Laboratories, Inc. $IDXX Shares Sold by Machina Capital S.A.S.

Machina Capital S.A.S. trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 85.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,380 shares of the company’s stock after selling 7,807 shares during the period. Machina Capital S.A.S.’s holdings in IDEXX Laboratories were worth $721,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $25,000. Elevation Wealth Partners LLC boosted its position in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. purchased a new stake in IDEXX Laboratories in the third quarter worth $29,000. Arlington Trust Co LLC grew its stake in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the period. Finally, Bell Investment Advisors Inc grew its stake in IDEXX Laboratories by 45.5% in the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after purchasing an additional 20 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on IDXX shares. UBS Group increased their price objective on IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Jefferies Financial Group dropped their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a report on Tuesday, October 20th. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th. Finally, Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $717.27.

Get Our Latest Report on IDEXX Laboratories

IDEXX Laboratories Price Performance

IDXX stock opened at $704.23 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. The firm has a market cap of $55.48 billion, a PE ratio of 47.49 and a beta of 1.55. The business has a 50 day moving average of $562.41 and a 200 day moving average of $573.52.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the previous year, the business earned $3.22 earnings per share. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.

Insider Activity

In other news, Director Daniel Junius sold 1,200 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the transaction, the director directly owned 2,361 shares in the company, valued at $1,662,309.27. This trade represents a 33.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Mazelsky sold 25,140 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the transaction, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This represents a 23.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 41,428 shares of company stock valued at $28,567,934. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.